AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Coiled-coil domain-containing protein 78

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

A2IDD5

UPID:

CCD78_HUMAN

Alternative names:

hsCCDC78

Alternative UPACC:

A2IDD5; B4DNY4; B4E1U6; Q05BY7; Q05CA0; Q6T2V5; Q6ZR33; Q8IUR3; Q8NAY7; Q96S12

Background:

Coiled-coil domain-containing protein 78 (hsCCDC78) plays a pivotal role in cell biology as a component of the deuterosome. This structure is crucial for de novo centriole amplification in multiciliated cells, enabling the generation of over 100 centrioles. Its function is essential for centriole amplification and CEP152 localization, occurring in terminally differentiated multiciliated cells outside of the S phase.

Therapeutic significance:

The association of hsCCDC78 with Myopathy, centronuclear, 4, a congenital muscle disorder, underscores its clinical importance. Understanding the role of hsCCDC78 could open doors to potential therapeutic strategies for this progressive muscular weakness and wasting disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.